Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

Eli Lilly and QurCan sign genetic medicine deal

QurCan will optimise genetic therapeutics using its technology, with Lilly overseeing further research and commercialisation.

Latest news

Electra targets $342m IPO to fund hyperinflammatory syndrome drug’s pivotal trials

Electra likens its targeted approach in immune-mediated disease to what precision oncology has achieved in cancer.

Gilead and PAHO agree to expedite lenacapavir access for HIV prevention

The collaboration enables 14 countries to access lenacapavir for PrEP outside of Gilead’s current voluntary licensing agreements.

Agentic AI trust gap slowing healthcare provider adoption, survey reveals 

As healthcare providers begin to embed agentic AI into their workflows, effective governance and multi-disciplinary accountability becomes key.

ERS 2026: obesity, an independent obstruction to biologic-treated asthma

For the purpose of this single-centre observational study, 82 patients who were prospectively treated with biologics were included.

GSK bolsters oncology pipeline with $750m Chimagen TCE deal  

GSK plans to take the TCE to Phase I clinical trials in multiple myeloma during 2027.